Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elanco Animal HealthELAN +1.17%68 EV-to-EBITDA is 20.00 as of Aug. 24, 2026, which is 6% below its 10-year median of 21.23. GuruFocus rates ELAN with a GF Score™ of 68/100 and a GF Value™ of $16.66 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, Elanco Animal Health ranks worse than 66.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elanco Animal Health's enterprise value is $15,504 Mil.
Elanco Animal Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $775 Mil. Therefore, Elanco Animal Health's EV-to-EBITDA for today is 20.00.
The historical rank and industry rank for Elanco Animal Health's EV-to-EBITDA or its related term are showing as below:
ELAN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2229.06 Med: 21.23 Max: 695.77
Current: 20
During the past 11 years, the highest EV-to-EBITDA of Elanco Animal Health was 695.77. The lowest was -2229.06. And the median was 21.23.
ELAN's EV-to-EBITDA is ranked worse than 66.98% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.2
vs ELAN: 20.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Elanco Animal Health (NYSE:ELAN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elanco Animal Health's PE Ratio (TTM) for today is calculated as:
Elanco Animal Health's share price for today is $24.25.
Elanco Animal Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Elanco Animal Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's EV-to-EBITDA falls into.
Elanco Animal Health's current Enterprise Value is $15,504 Mil.
Elanco Animal Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $775 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (ELAN) has a EV-to-EBITDA of 20.00 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elanco Animal Health. This is near median its historical median of 21.23. According to the industry distribution chart, Elanco Animal Health ranks #495 out of 739 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is Elanco Animal Health's EV-to-EBITDA too high?
Elanco Animal Health's current EV-to-EBITDA of 20.00 is near median its 10-year median of 21.23. The Drug Manufacturers industry median EV-to-EBITDA is 13.20. Elanco Animal Health's value of 20.00 is 51.5% above this industry median. Based on the distribution chart, Elanco Animal Health ranks #495 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Elanco Animal Health has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's EV-to-EBITDA compare to ALKS and LQDA?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #495 out of 739 companies for EV-to-EBITDA. This places Elanco Animal Health in the lower half of its industry. The industry median EV-to-EBITDA is 13.20. Elanco Animal Health's value of 20.00 is 51.5% above this benchmark. While the company's 10-year median is 21.23 vs. the industry median of 13.20, Elanco Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.20, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elanco Animal Health's current EV-to-EBITDA of 20.00 is 51.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elanco Animal Health. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current EV-to-EBITDA is 20.00, which is near median its own 10-year median of 21.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.66, compared to a current price of $24.25 — trading 45.6% above its estimated fair value. The current EV-to-EBITDA is 20.00, which is near median its 10-year median of 21.23 and 51.5% above the Drug Manufacturers industry median of 13.20. Elanco Animal Health's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current EV-to-EBITDA is 20.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $24.25 is trading 45.6% above its estimated GF Value™ of $16.66.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
EV-to-EBITDA: 20.00 (near median its 10-year median of 21.23)
GF Value™: $16.66 vs. price of $24.25 (45.6% above fair value)
Industry Position: 51.5% above the Drug Manufacturers median (#495 of 739)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
68GF Score
Get the complete analysis for ELAN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
